Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023, Volume: 64, Issue:1
Aggressive cancers such as triple-negative breast cancer (TNBC) avidly metabolize glutamine as a feature of their malignant phenotype. The conversion of glutamine to glutamate by the glutaminase enzyme represents the first and rate-limiting step of this pathway and a target for drug development. Indeed, a novel glutaminase inhibitor (GLSi) has been developed and tested in clinical trials but with limited success, suggesting the potential for a biomarker to select patients who could benefit from this novel therapy. Here, we studied a nonmetabolized amino acid analog, Topics: Animals; Biomarkers; Carboxylic Acids; Cyclobutanes; Glutaminase; Glutamine; Humans; Kinetics; Mice; Positron-Emission Tomography; Triple Negative Breast Neoplasms | 2023 |